Figure 4 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

Changes in proportions of T-cell populations with anti–PD-1 via high-parameter flow cytometry. A, Change in abundance of T-cell subtypes with initiation of retifanlimab in patients with paired biopsies and detectable tumor-infiltrating T cells. B, Boxplot depicting percent change post- vs. pre-retifanlimab in the abundance of 63 T cell types. Filled boxes with bold labels and asterisks indicate T cell subsets with significant changes (P < 0.05; FDR < 0.05). C and D, Percent change in four key subsets of (C) CD4+ and (D) CD8+ T cells. OR, overall response.